title: [Drug reactions caused by chemotherapy agents].
abstract: In recent years, several new classes of compounds have successfully been established in the treatment of cancer. They selectively inhibit disturbed signaling pathways or induce anti-tumor immune responses. These novel targeted cancer drugs show a favorable safety profile compared to conventional chemotherapeutic agents. The most important side effects of these anticancer agents include cutaneous reactions and occur in a time-dependant manner and show class-specific patterns. In this review article, we compare the cutaneous side effects of epidermal growth factor inhibitors (EGFRI), multikinase inhibitors (MKI), BRAF inhibitors (BRAFI), mTor inhibitors (mTorI) and immune checkpoint inhibitors and discuss severity-adapted management strategies.
authors.affiliation: Hautklinik, Medizinische Fakultät der Heinrich-Heine-Universität Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Deutschland.
authors.forename: L M
authors.initials: LM
authors.lastname: Ehmann
authors.forename: H
authors.initials: H
authors.lastname: Schrumpf
authors.forename: P A
authors.initials: PA
authors.lastname: Gerber
authors.forename: B
authors.initials: B
authors.lastname: Homey
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D003875:Drug Eruptions / Q000175:diagnosis* / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D058990:Molecular Targeted Therapy / Q000009:adverse effects*
chemical_list: D000970:Antineoplastic Agents